Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients

"Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) will be measured by transient liver elastometry Fibroscan to evaluate hepatic steatosis and fibrosis in all patients at baseline. Absence of steatosis S0 is defined as CAP \<248 dB/m, mild steatosis S1 with CAP \< 268 dB/m, and moderate to severe steatosis ≥ S2 is defined as CAP \>280 dB/m. Liver fibrosis will be evaluated using the liver stiffness measurement (LSM) in kPa7."